Paper Infomation
Expression of Epitope Vaccine CTB-UA against Helicobacter Pylori in Transgenic Tomato
Full Text(PDF, 3353KB)
Author: Xiaokang Li, Xinyang Li, Xuanquan Wang, Le Guo, Yingying Xing, Tao Xi
Abstract: Helicobacter pylori is a key reason for Stomach diseases, and how to eradicate Helicobacter pylori has been studied for several decades. Oral vaccines produced by transgenic plants would change the traditional means of production and inoculation of Helicobacter pylori vaccines and reduce the vaccination cost significantly. In this research for the first time we used the transgenic tomato system to express Helicobacter pylori epitope vaccine CTB-UA, a recombinant peptide which could protect BALB/c mice from Helicobacter pylori infection after oral immunization by increasing the specific antibodies. CTB-UA was transformed into tomato mediated by Agrobacterium tumifient EHA105, and transgenic shoots have been verified by PCR analysis, RT-PCR and Enzyme-linked immunosorbent assay (ELISA) analysis showed that CTB-UA gene could transcript and produce the target peptide in the roots, fruits and leaves from the three transgenic tomato lines. Transgenic tomato derived oral vaccine strategy could be potentially used as an alternative strategy to fight for the H. pylori infection, especially for the people in developing worlds.
Keywords: Helicobacter Pylori; CTB-UA; Transgenic Tomato; Plant Vaccine
References:
[1] Sutton Y.-T. C. P. Targeting of whole killed bacteria to gastrointestinal M-cells induces humoral immunity in the female reproductive tract. Infection and Immunity, July 2009, p. 2009; 77: 2962-70
[2] Tas A., Akbal E., Kocak E. and Koklu S. Moxifloxacin-tetracycline-lansoprazole triple therapy for first-line treatment of Helicobacter pylori infection: a prospective study. Helicobacter 2011; 16: 52-4
[3] Rothenbacher D. and Brenner H. Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes Infect 2003; 5: 693-703
[4] Suzuki H., Saito Y. and Hibi T. Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis. Gut Liver 2009; 3: 81-7
[5] Mendall M. A. Transmission of Helicobacter pylori. Semin Gastrointest Dis 1997; 8: 113-23
[6] Del Giudice G., Covacci A., Telford J. L., et al. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 2001; 19: 523-63
[7] Blanchard T. G., Eisenberg J. C. and Matsumoto Y. Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. Vaccine 2004; 22: 888-97
[8] Gisbert J. P. and Pajares J. M. Treatment of Helicobacter pylori infection: the past and the future. Eur J Intern Med 2010; 21: 357-9
[9] Tang R. X., Luo D. J., Sun A. H. and Yan J. Diversity of Helicobacter pylori isolates in expression of antigens and induction of antibodies. World J Gastroenterol 2008; 14: 4816-22
[10] Agarwal K. and Agarwal S. Helicobacter pylori vaccine: from past to future. Mayo Clin Proc 2008; 83: 169-75
[11] Remes-Troche J. [Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study.]. Rev Gastroenterol Mex 2008; 73: 254
[12] Daniell H., Singh N. D., Mason H. and Streatfield S. J. Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 2009; 14: 669-79
[13] Tiwari S., Verma P. C., Singh P. K. and Tuli R. Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv 2009; 27: 449-67
[14] Takahashi I., Nochi T., Yuki Y. and Kiyono H. New horizon of mucosal immunity and vaccines. Curr Opin Immunol. 2009; 21: 352-8
[15] Salyaev, R. K., et al. Study of the mucosal immune response duration in mice after administration of a candidate edible vaccine based on transgenic tomato plants carrying the TBI-HBS gene. Dokl Biochem Biophys 2009; 428: 232-234
[16] Shchelkunov, S. N., et al. Study of immunogenic properties of the candidate edible vaccine against human immunodeficiency and hepatitis B viruses based on transgenic tomato fruits. Dokl Biochem Biophys 2005 401: 167-169
[17] Shchelkunov, S. N., et al. Designing of a candidate edible vaccine against hepatitis B and HIV on the basis of a transgenic tomato. Vestn Ross Akad Med Nauk 2004; 11: 50-55
[18] Ryo Matsuda, Chieri Kubota, M. Lucrecia Alvarez, and Guy A. Cardineau. Effect of high electrical conductivity of hydroponic nutrient solution on vaccine protein content in transgenic tomato. Hort Technology 2012; 22: 362-367
[19] Zheng-jun Guan, Bin Guo., Hao-yong Hao., et.al. Expression of hepatitis B surface antigen (HBsAg) gene in transgenic cherry tomato. 2012; 11: 7186-7192
[20] Le Guo, Xiaokang Li and Tao Xi., et al. Immunological features and the ability of inhibitory effects on enzymatic activity of an epitope vaccine composed of cholera toxin B subunit and B cell epitope from Helicobacter pylori urease A subunit. Appl Microbio Biotechnol 2012; 93: 1937-1945
[21] 21. Le Guo, Kunmei Liu and Tao Xi, et al. Prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA against Helicobacter pylori infection in a BALB/c mice model. Appl Microbio Biotechnol 2012; 95: 1437-1444